2 TITLE PAGE

Take home key practical strategies from the new treatment guidelines and evidence-based solutions for managing your complex patients

Decipher the most recent clinical data to apply directly to your practice

Connect with leading experts in cardiometabolic health for answers to your most urgent questions

Preview cutting-edge products and services featured in the CMHC Exhibit Hall and Professional Education

2 TITLE PAGE Boston, MA

WHY YOU SHOULD ATTEND THE CMHC

“This is my third time attending the Cardiometabolic Health Congress. Once again, the information given was cutting-edge, clinically relevant and readily applicable. For sure, attending the CMHC will be an annual event for my continuing medical education.”

- Oscar Giron, MD (Mundelein, IL)

“An excellent, multidisciplinary Congress! I enjoyed learning of late-breaking advances in care that provide possible treatment options for my patients.”- Carina Katigbak, PhD (Boston, MA)

“I fi nd the CMHC provides more useful clinical information and evidence-based medicine that I can apply to my practice than all the pharmacy conferences combined! This is my favorite conference and I wish I couldattend every year!”- Megan Undeberg, PharmD (Duluth, MN)

[[The 2014 Cardiometabolic Health Congress

will translate the latest medical research intopractical, clinical approaches for preventing, delaying, and

managing cardiovascular and metabolic risk.

EARN 27.5UPTO

CME/CE CREDITS

TITLE PAGE 3

Chairpersons & Faculty 4-5

Program Agenda 6-8

CME Symposia 8-10

Program Overview 11

Accreditation 11

Professional Education 12

Exhibitor Information 13

Hotel & Travel 14

Association Supporters 14

Publication Supporters 14

Registration Form 15

TAB

LE O

F C

ON

TEN

TS

9th Annual

Join our renowned faculty – along with 44 prestigious medical associations and 1,500 of your colleagues – as they present expert clinical perspectives,

frontline research and a complete educational experience addressing today’s cardiometabolic disease epidemic.[

[

4 CHAIRPERSONS & FACULTY

CHAIRPERSONS & FACULTYChristie M. Ballantyne, MDProfessor of MedicineChief, Section of Cardiovascular ResearchChief, Section of CardiologyDepartment of Medicine, Baylor College of MedicineDirector, Center for Cardiovascular Disease PreventionBaylor College of MedicineMethodist DeBakey Heart Center

Jay S. Skyler, MD, MACPProfessor of Medicine, Pediatrics, & PsychologyDivision of Endocrinology, Diabetes & MetabolismUniversity of Miami Miller School of MedicineDeputy Director for Clinical & Academic ProgramsDiabetes Research Institute

Robert H. Eckel, MD Professor of MedicineDivision of Endocrinology, Metabolism and DiabetesDivision of CardiologyProfessor of Physiology and BiophysicsCharles A. Boettcher II Chair in AtherosclerosisDirector, Discovery TranslationColorado Clinical & Translational Science InstituteUniversity of Colorado Anschutz Medical CampusDirector, Lipid Clinic, University Hospital

George L. Bakris, MDProfessor of MedicineDirector, ASH Comprehensive Hypertension CenterUniversity of Chicago Medicine Pritzker School of Medicine

C. Ronald Kahn, MDMary K. Iacocca ProfessorHarvard Medical SchoolChief Academic Offi cerJoslin Diabetes Center

Lee M. Kaplan, MD, PhDAssociate Professor of MedicineHarvard Medical SchoolDirectorObesity, Metabolism & Nutrition InstituteMassachusetts General Hospital

Jamy D. Ard, MDAssociate Professor, Div. of Public Health SciencesDepartment of Epidemiology & PreventionWake Forest School of MedicineCo-Director, Weight Management CenterMedical Director, Medical Weight Loss ProgramWake Forest Baptist Health

Jeff rey L. Anderson, MDProfessor of MedicineUniversity of Utah School of MedicineAssociate Chief of CardiologyDirector, Cardiovascular ResearchIntermountain Heart InstituteIntermountain Medical Center

Catherine Davis AhmedFH Advocate and Director of OutreachThe FH Foundation

Caroline M. Apovian, MDProfessor of MedicineBoston University School of MedicineDirectorCenter for Nutrition and Weight ManagementBoston Medical Center

Deepak L. Bhatt, MD, MPHProfessor of MedicineHarvard Medical SchoolExecutive DirectorInterventional Cardiovascular ProgramsBrigham and Women’s HospitalHeart and Vascular Center

Eliot A. Brinton, MDDirectorAtherometabolic ResearchUtah Foundation for Biomedical Research

Rebecca J. Brown, MDAssistant Clinical InvestigatorNational Institute of Diabetes and Digestiveand Kidney DiseasesNational Institutes of Health

John B. Buse, MD, PhDVerne S. Caviness Distinguished ProfessorChief, Division of EndocrinologyDirector, Diabetes Care CenterExecutive Associate Dean for Clinical ResearchUniversity of North Carolina School of Medicine

Samuel Dagogo-Jack, MDProfessor of MedicineDir., Div. of Endocrinology, Diabetes & MetabolismA. C. Mullins Chair in Translational ResearchDirector, General Clinical Research CenterDirector, Endocrinology Fellowship Training ProgramUniversity of Tennessee Health Science Center

Edward R. Damiano, PhDAssociate ProfessorBiomedical EngineeringBoston University

Michael H. Davidson, MDClinical ProfessorDirector of the Lipid ClinicThe University of ChicagoPritzker School of Medicine

Honey E. EastEndocrinologistPremier Medical Group of Mississippi

Keith C. Ferdinand, MDProfessor of Clinical MedicineTulane University School of Medicine Chair, National Forum for HeartDisease and Stroke Prevention

Sarah de Ferranti, MD, MPHDirectorPreventive Cardiology ProgramAssistant Professor of PediatricsHarvard Medical School

JoAnne M. Foody, MD Associate ProfessorHarvard Medical SchoolMedical DirectorCardiovascular Wellness ProgramBrigham and Women’s Hospital

Louis J. Aronne, MDSanford I. Weill Professor of Metabolic ResearchMedical DirectorCenter for Weight Mgmt. & Metabolic Clinical ResearchWeill-Cornell Medical College

Suzanne V. Arnold, MD, MHAClinical Scholar and CardiologistSaint Luke’s Mid America Heart InstituteResearch Assistant ProfessorDepartment of Biomedical & Health InformaticsUniversity of Missouri-Kansas City

Lawrence Blonde, MDDirectorOchsner Diabetes Clinical Research UnitDepartment of EndocrinologyOchsner Medical Center

George A. Bray, MDBoyd ProfessorChiefDivision of Clinical Obesity and MetabolismPennington Biomedical Research Center

Harold E. Bays, MDMedical Director/PresidentLouisville Metabolic and AtherosclerosisResearch Center, Inc.

Seth J. Baum, MDMedical Director, Women’s Preventive CardiologyChristine E. Lynn Women’s Health & Wellness InstituteBoca Raton Regional HospitalVoluntary Associate Professor of MedicineMiller School of MedicineUniversity of Miami

Robert A. Harrington, MDArthur L. Bloomfi eld Professor of MedicineChairman of the Department of MedicineStanford University

Scott M. Grundy, MD, PhDDirector, Center for Human NutritionDistinguished Professor of Internal MedicineUniversity of Texas Southwestern Medical CenterAssistant Chief, Research in the Medical ServiceVeterans Aff airs Medical Center

Thomas Giles, MDClinical Professor of MedicineHeart and Vascular InstituteTulane University School of Medicine

Martha M. Funnell, MS, RN, CDEAssociate Research ScientistDepartment of Learning Health SciencesUniversity of Michigan Medical School

Abhimanyu Garg, MDProfessor of Internal MedicineChiefDivision of Nutrition and Metabolic DiseasesUniversity of Texas Southwestern Medical Center

Terry A. Jacobson, MDPresident, National Lipid AssociationProfessor of MedicineEmory UniversityDirectorOffi ce of Health Promotion & Disease PreventionCo-Director, Lipid & CV Risk Reduction ProgramGrady Health Systems

Michael D. Jensen, MDThomas J. Watson, Jr.Professor in Honor of Dr. Robert L. FryeMayo College of MedicineDirector, Department of MedicineObesity Treatment Research ProgramMayo Clinic

CHAIRPERSONS & FACULTY 5

Peter H. Stone, MD Associate Professor of MedicineHarvard Medical SchoolCo-Director, Samuel A. Levine Cardiac UnitDirector, Clinical Trials CenterBrigham and Women’s Hospital

Colleen M. Majewski, MDAssistant Professor of MedicineSection of Endocrinology, Diabetes & MetabolismThe University of Chicago MedicineEndocrinologistDuchossois Center for Advanced Medicine

Sekar Kathiresan, MDAssociate Professor of MedicineHarvard Medical SchoolDirector, Preventive CardiologyMassachusetts General Hospital

Peter Libby, MD Mallinckrodt Professor of MedicineHarvard Medical SchoolChief of Cardiovascular MedicineBrigham and Women’s Hospital

Gary A. Puckrein, PhDChief Executive Offi cerNational Minority Quality Forum

Daniel M. Riche, PharmD, BCPS, CDEAssociate Professor of Pharmacy PracticeThe University of Mississippi School of PharmacyAssociate Professor of MedicineThe University of Mississippi Medical CenterClinic Coordinator, Cardiometabolic Clinic

Scott RadabaughFH AdvocateThe FH Foundation

Paul M. Ridker, MD, MPHEugene Braunwald Professor of MedicineHarvard Medical SchoolDirector, Center for CardiovascularDisease PreventionBrigham and Women’s Hospital

Evan Stein, MD, PhDDirector EmeritusMetabolic & Atherosclerosis Research Center

P. Gabriel Steg, MDProfessor, Cardiology DepartmentParis Diderot UniversityDirector, Coronary Care UnitHospital Bichat-Claude Bernard

Neil J. Stone, MD Bonow Professor of MedicineFeinberg School of Medicine, Northwestern UniversitySuzanne & Milton Davidson Distinguished PhysicianMedical DirectorVascular Center of the Bluhm CV InstituteNorthwestern Memorial Hospital

Andra Stratton Co-Founder and PresidentLipodystrophy United

James A. Underberg, MDClinical Assistant Professor of MedicineNYU Medical SchoolNYU Center for CVD PreventionDirector, Bellevue Hospital Lipid Clinic

Laurence S. Sperling, MDProfessor of Medicine (Cardiology)Director, Emory Heart Disease Prevention CenterEmory University School of Medicine Professor of Global HealthHubert Department of Global HealthRollins School of Public Health at Emory University

Joshua Thaler, MD, PhDAssistant ProfessorDivision of Metabolism, Endocrinology & Nutrition University of Washington Department of Medicine

Peter J. Turnbaugh, PhDAssistant ProfessorDepartment of Microbiology & ImmunologyG.W. Hooper Research FoundationUniversity of California, San Francisco

Kris Vijay, MDVice President Scottsdale Cardiovascular CenterClinical Professor of MedicineUniversity of Arizona College of Medicine

Thomas A. Wadden, PhDProfessor of PsychologyDepartment of PsychiatryPerelman School of MedicineUniversity of PennsylvaniaDirector, Center for Weight and Eating Disorders

Matthew R. Weir, MDProfessor and DirectorDivision of NephrologyUniversity of Maryland School of Medicine

Michael A. Weber, MDProfessor of MedicineState University of New YorkDownstate College of Medicine

Mark E. Molitch, MDMartha Leland Sherwin Professor of EndocrinologyDivision of EndocrinologyMetabolism and Molecular MedicineNorthwestern UniversityFeinberg School of Medicine

William E. Kraus, MDProfessor of MedicineDuke University School of Medicine

Virend K. Somers, MD, PhD Professor of MedicineMayo ClinicConsultant in Cardiovascular DiseasesMayo Clinic and Mayo Foundation

Francesco Rubino, MDProfessor and ChairBariatric & Metabolic SurgeryKing’s College London, UK

Marc S. Sabatine, MD, MPHChairman, TIMI Study GroupAssociate Physician in Cardiovascular MedicineBrigham and Women’s HospitalAssociate Professor of MedicineHarvard Medical School

Sidney C. Smith, Jr., MDProfessor of MedicineDirectorCenter for Cardiovascular Science and MedicineThe University of North Carolina in Chapel Hill

Pamela B. Morris, MDDirectorSeinsheimer Cardiovascular Health ProgramCo-Director, Women’s Heart CareMedical University of South Carolina

Patrick M. Moriarty, MDDirectorAtherosclerosis/LDL-Apheresis CenterProfessor of MedicineUniversity of Kansas Medical Center

Dariush Mozaff arian, MD, DrPHDean, Friedman School of Nutrition Science & PolicyTufts University

Michael Miller, MDProfessor of Medicine, Epidemiology & Public HealthUniversity of Maryland School of MedicineDirector, Center for Preventive CardiologyUniversity of Maryland Medical Center

Aldo J. Peixoto, MDProfessor of Medicine, NephrologyYale School of MedicineAssociate Chair, Ambulatory Operations & QualityDepartment of Internal MedicineClinical Chief, Section of NephrologyDirector, Yale Hypertension Center

Sunder Mudaliar, MDClinical Professor of MedicineUniversity of California, San Diego

Elif A. Oral, MDAssociate Professor of Internal MedicineDirector, Post-Bariatric Surgery ClinicMedical DirectorUniversity of Michigan Hospital & Health SystemsBariatric Surgery Program

Richard E. Pratley, MDDirector, Florida Hospital Diabetes InstituteSenior Scientist, Translational Research Institute for Metabolism and DiabetesProfessorSanford Burnham Medical Research Institute

Howard A. Wolpert, MDSenior PhysicianJoslin Diabetes Center

6 PROGRAM AGENDA

PROGRAM AGENDAProfessional Education (non-CME)

Thursday, October 23, 20146:15 – 7:45am

CME Breakfast Symposia A, B

SESSION I:DYSLIPIDEMIA, ATHEROSCLEROSIS ANDCARDIOVASCULAR DISEASE RISK REDUCTION

8:00 – 8:10am

Opening Remarks

Christie M. Ballantyne, MD

8:10 – 9:40am

CVD Prevention Guidelines Update:

Clinical Impact and Current Controversies

Christie M. Ballantyne, MD (moderator); George L. Bakris, MD;

Robert H. Eckel, MD; Scott M. Grundy, MD, PhD;

Jay S. Skyler, MD; Sidney C. Smith, Jr., MD; Neil J. Stone, MD

9:40 – 10:30am

Keynote SessionUpdate on Infl ammation in the Pathogenesis

of Cardiometabolic Disease

Peter Libby, MD

Testing the Infl ammation Hypothesis:

The CIRT and CANTOS Trials

Paul M. Ridker, MD, MPH

10:30 – 11:30am

Morning Break/Exhibit Hall

11:30am – 12:30pm

Late-Breaking Clinical Trials and FDA Update

Christie M. Ballantyne, MD (moderator);

Deepak L. Bhatt, MD, MPH; Robert H. Eckel, MD;

Keith C. Ferdinand, MD; Jay S. Skyler, MD

12:45 – 2:15pm

CME Lunch Symposia A, B, C

2:30 – 3:30pm

Expert Debates in Antithrombotic Therapy· Do diabetic patients with CAD need more than just aspirin?

· Should patients with stents receive DAPT for more than a year?

· Should patients with AFib receive novel anticoagulants?

Deepak L. Bhatt, MD, MPH; Robert A. Harrington, MD; P. Gabriel Steg, MD

3:30 – 4:15pm

Afternoon Break/Exhibit Hall

4:15 – 4:45pm

Keynote SessionImplications of Recent Genetic Findings on

Management of Cardiovascular Risk

Sekar Kathiresan, MD

4:45 – 5:45pm

Clinical Controversies in Lipid Management:

Case-Based Presentations and Discussion

Christie M. Ballantyne, MD (moderator); Robert H. Eckel, MD;

JoAnne M. Foody, MD; Sekar Kathiresan, MD; Neil J. Stone, MD

5:45pm

Closing Remarks

Christie M. Ballantyne, MD

5:45 – 7:00pm

Join us in the Exhibit Hall

for our Welcome Reception

7:00 – 9:00pm

CME Dinner Symposia A, BAgenda and faculty are subject to change.

Friday, October 24, 2014

6:00 – 7:00pm

Take a Closer Look at Homozygous

Familial Hypercholesterolemia

Daniel E. Wise, MD

Sponsored by Aegerion Pharmaceuticals

6:00 – 7:00pm

Treatment Considerations for

Generalized Lipodystrophy

Jean Chan, MD

Sponsored by AstraZeneca

Wednesday, October 22, 2014

11:15am – 12:30pm

The Eff ect of a Once-Weekly Therapy on

A1C and Weight Over 3 Years

Neil I. Kaminsky, MD

Sponsored by AstraZeneca Diabetes

12:30 – 2:00pm • Lunch

Advancing Paradigm Changes in

Type 2 Diabetes Management

Robert Busch, MD

Sponsored by Janssen Pharmaceuticals, Inc.

2:00 – 3:15pm

Addressing Chronic Weight Management

with Targeted Pharmacotherapy

Harold E. Bays, MD

Sponsored by Eisai, Inc.

3:15 – 4:30pm

Understanding High Triglycerides

JoAnne M. Foody, MD

Sponsored by AstraZeneca

4:30 – 5:45pm

SGLT2 Inhibition: A Glucuretic Treatment Option

for Your Adult Patients With Type 2 Diabetes

Neil I. Kaminsky, MD

Sponsored by AstraZeneca Diabetes

5:45 – 7:00pm

Chronic Weight Management in Adults:

A Treatment Option

Harold E. Bays, MD

Sponsored by Takeda Pharmaceuticals America, Inc.

Wednesday, October 22, 2014 (cont.)

7:00 – 8:30pm • Dinner

New Diagnostic Tools for the Prevention and

Comprehensive Management of Diabetes

Timothy E. Graham, MD

Sponsored by Health Diagnostic Laboratory, Inc.

For session details, see page 12.

These non-certifi ed activities are not part of the offi cial CMHC program and are planned solely by the sponsoring organizations/companies.

6:15 – 7:45am

CME Breakfast Symposia A, B, C

SESSION II:HYPERTENSION AND CARDIO-RENAL SYNDROME

8:00 – 8:10am

Opening Remarks

George L. Bakris, MD

8:10 – 8:40am

Low Diastolic BP and Progression to CKD

Aldo J. Peixoto, MD

8:40 – 9:10am

Device Therapy and Resistant Hypertension

George L. Bakris, MD

9:10 – 9:40am

New Methodologies for the Management of

Hyperkalemia in Kidney Disease

Matthew R. Weir, MD

9:40 – 10:10am

The Contribution of Aldosterone in

Obesity-Related Hypertension

Colleen M. Majewski, MD

10:10 – 11:15am

Morning Break/Exhibit Hall

11:15am – 12:15pm

Clinical Controversies in Hypertension Management

George L. Bakris, MD (moderator); Colleen M. Majewski, MD;

Aldo J. Peixoto, MD; Matthew R. Weir, MD

12:30 – 2:00pm

CME Lunch Symposia A, B, C

Friday, October 24, 2014

SESSION III:DIABETES MANAGEMENT

2:00 – 2:30pm

Is Alzheimer’s Disease Type 3 Diabetes?

C. Ronald Kahn, MD

2:30 – 3:00pm

Type 2 Diabetes Management 2014

John B. Buse, MD, PhD

3:00 – 3:30pm

Initiating and Monitoring Insulin Therapy

Howard A. Wolpert, MD

3:30 – 4:15pm

Afternoon Break/Exhibit Hall

4:15 – 4:45pm

The Bionic Pancreas

Edward R. Damiano, PhD

4:45 – 5:45pm

Diabetes Panel Session

Jay S. Skyler, MD (moderator); John B. Buse, MD, PhD;

Edward R. Damiano, PhD; C. Ronald Kahn, MD;

Howard A. Wolpert, MD

5:45pm

Closing Remarks

Jay S. Skyler, MD

6:00 – 7:00pm

Professional Education A, B (non-CME)

7:00 – 9:00pm

CME Dinner Symposia A, B

(non-CME)

Agenda and faculty are subject to change.

PROGRAM AGENDA 7

)

For CME Symposia details, see pages 8 – 10.

“This is the CME I have been looking for! Excellent combinations of basic science and clinical practice,

as well as endocrinology and cardiology grouping.

I truly feel educated.”- Jun Liang, MD (Savage, MN)

“As a primary care physician,if I could attend only

one conference each year, the CMHC would be that conference.”

- Atul Soreng, MD (Bangor, ME)

“A++ program. Better than some ADA and AADE programs. I especially

enjoy the general sessions, group presentations and discussions.”

- Judith Pentedemos, FNP (Ayer, MA)

8 PROGRAM AGENDA / CME SYMPOSIA

Saturday, October 25, 201410:15 – 11:00am

Long-Term Use of Obesity Medications:

How to Sustain Weight Loss

Caroline M. Apovian, MD

11:00 – 11:30am

Behavioral Strategies in Obesity Management

Thomas A. Wadden, PhD

11:30 – 11:50am

Role of Exercise in the Modulation of Nontraditional

CHD Risk Factors

William E. Kraus, MD

11:50am – 12:30pm

Obesity Panel Discussion

Robert H. Eckel, MD (moderator); Caroline M. Apovian, MD;

Lee M. Kaplan, MD, PhD; William E. Kraus, MD;

Francesco Rubino, MD; Virend K. Somers, MD, PhD;

Peter J. Turnbaugh, PhD; Thomas A. Wadden, PhD

12:30pm

Closing Remarks

Robert H. Eckel, MD

6:15 – 7:45am

CME Breakfast Symposium

SESSION IV: LIFESTYLE AND OBESITY MANAGEMENT

8:00 – 8:10am

Opening Remarks

Robert H. Eckel, MD

8:10 – 8:50am

Impact of Gut Microbiota on Obesity and CVD Risk

Peter J. Turnbaugh, PhD

8:50 – 9:30am

Long-Term Eff ects of Metabolic Surgery

Lee M. Kaplan, MD, PhD; Francesco Rubino, MD

9:30 – 10:00am

Sleep Apnea and Restricted Sleep Patterns:

Impact on Cardiometabolic Health

Virend K. Somers, MD, PhD

10:00 – 10:15am

Morning Break

Thursday, October 23, 2014CME Breakfast Symposium A • 6:15 – 7:45amThe Triglycerides Conundrum:Practical Clinical Guidance for Reducing Residual CV RiskHarold E. Bays, MD (Chair); Eliot A. Brinton, MD; Scott M. Grundy, MD, PhD

Hypertriglyceridemia is an increasingly relevant issue facing clinicians in their routine practice. Our faculty will address current controversies in triglyceride management and provide expert insight on how to eff ectively managepersistently elevated triglycerides in patients who remain at high CV risk. This symposium will evaluate triglyceride-lowering therapies, with a focus onomega-3 fatty acids, comparing and contrasting data on their safety,tolerability, lipid-lowering eff ects and cardio-protective benefi ts. Supported by an educational grant from Amarin Pharma, Inc.

CME Breakfast Symposium B • 6:15 – 7:45amConfronting Racial and EthnicDisparities in Cardiometabolic Disease

Laurence S. Sperling, MD (Chair); Gary A. Puckrein, PhD;Keith C. Ferdinand, MD; JoAnne M. Foody, MD; Kris Vijay, MD

Multiple mechanisms interact in complex ways to contribute to health status, including social class, genetics, personal health behavior and utilization of medical care. Our faculty will provide systemic approaches to reduce disparities and proven clinical strategies to combat cardiometabolic disease in ethnic minority populations. This symposium is jointly provided by the American College of Cardiology, in collaboration with the National Minority Quality Forum and Association of Black Cardiologists. Sponsored by the American College of Cardiology in collaboration with the National Minority Quality Forum and the Association of Black Cardiologists | Supported in part by educational grants from Arbor Pharmaceuticals and Merck & Co.

CME Lunch Symposium A • 12:45 – 2:15pmObesity Management 2014: New Perspectives andTherapeutic Options for a Growing ProblemRobert H. Eckel, MD (Chair); Jamy D. Ard, MD;George A. Bray, MD; Michael D. Jensen, MD

Type 2 diabetes and obesity are very much intertwined and treatment of each disease aff ects the other. This symposium will explore obesity’s biologic causes, clinical consequences, and the expanding armamentarium of weight control methods, especially in those special populations aff ected by prediabetes and diabetes. Clinicians will refi ne their ability to evaluate comorbidities and select obesity therapies that are safe, eff ective and individualized for patient needs.

Supported by an educational grant from Novo Nordisk, Inc.

CME Lunch Symposium B • 12:45 – 2:15pmClosing the Gaps in the Continuum of Care for Patientswith Acute Coronary Syndromes: Implications for Optimal Antiplatelet UseDeepak L. Bhatt, MD, MPH (Chair); Jeff rey L. Anderson, MD; Robert A. Harrington, MD; P. Gabriel Steg, MD

The manifestations of Acute Coronary Syndrome (ACS) are associated with high morbidity and mortality. This symposium will provide an update on major U.S. guideline recommendations concerning the use of P2Y12 inhibitors in patients with ACS. Our faculty of internationally recognized experts will present and analyze clinical trial data on the available P2Y12 inhibitors, with an emphasis on clinical data in high-risk patients such as the elderly, those with diabetes, and those with a prior history of stroke. Attendees will leave this activity better able to individualize antiplatelet therapy, improve outcomes and minimize hospital readmission rates.

Supported by an educational grant from AstraZeneca

Agenda and faculty are subject to change.

Participate in your choice of 16 CME symposia held each day of the Congress. Symposia include meals or refreshments and are ticketed

events that fi ll up quickly. Register for CMHC today to sign up for these value-added CME/CE activities—at no additional cost!

PROGRAM AGENDA

CME SYMPOSIA

CME SYMPOSIA 9

CME SYMPOSIAThursday, October 23, 2014 (continued)

CME Lunch Symposium C • 12:45 – 2:15pmEvolving Strategies for LDL-Lowering: Novel Target andTreatments for CVD Risk ReductionTerry A. Jacobson, MD (Chair); Eliot A. Brinton, MD; Sekar Kathiresan, MD;Evan A. Stein, MD, PhD

The latest CVD prevention guidelines published by national organizations have diverted signifi cantly from previous recommendations in that they abandoned target goals for lipid parameters in favor of focusing on statin treatment forhigh-risk patients. While statins remain fi rst-line therapy in LDL-C reduction,patients continue to experience residual risk or are unable to tolerate statins.

Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals

CME Dinner Symposium A • 7:00 – 9:00pmThe Wide Spectrum of Familial Hypercholesterolemia:Discovering Your Highest Risk Patients and Optimizing TreatmentSeth J. Baum, MD (Chair); Catherine Davis Ahmed; Sarah de Ferranti, MD, MPH;Patrick M. Moriarty, MD; Pamela B. Morris, MD; Scott Radabaugh

Worldwide, there are at least 20 million people with familial hypercholesterolemia (FH). Despite the availability of eff ective treatment options and the prevalence of the disease, FH is both underdiagnosed and undertreated. This symposium will address knowledge and practice gaps in the identifi cation and management of patients with severe FH. The faculty will provide expert recommendations for diagnosing FH and cascade family screening, and will present the most current evidence on novel therapeutic options. Patient Advocates from The FH Foundation will share their personal experiences with this life-threatening disease and eff orts to improve awareness and encourage proactive treatment.

Supported by educational grants from Aegerion Pharmaceuticals, Inc. and Genzyme, A SANOFI COMPANY | Endorsed by The FH Foundation

CME Dinner Symposium B • 7:00 – 9:00pm

Novel and Emerging Combinations to Achieve Glycemic Control and Reduce Cardiometabolic Risk: A Focus on Incretin-Based Therapy and SGLT2 InhibitorsGeorge L. Bakris, MD (Chair); Mark E. Molitch, MD;Sunder Mudaliar, MD; Richard E. Pratley, MD

Newer treatment options, including sodium glucose co-transporter-2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, and several fi xed-dose combinations are available or are under development and may change the treatment paradigm for T2DM. These evidence-based therapies have the potential to work synergistically in combination with other available interventions to achieve glycemic control and to reduce overall cardiometabolic risk for individuals with T2DM. This symposium will keep clinicians apprised of new clinical trial data and developments and discuss how to appropriately integrate these newer and emerging therapies into clinical practice.

Supported by an educational grant from AstraZeneca

rs

Friday, October 24, 2014CME Breakfast Symposium A • 6:15 – 7:45amOptimizing Antihypertensive Therapies in High-Risk andDiffi cult-to-Treat Patients with HypertensionGeorge L. Bakris, MD (Chair); Keith C. Ferdinand, MD;Thomas Giles, MD; Michael A. Weber, MD

Despite well-established risks, hypertension remains under-treated and, when treated, often stubbornly diffi cult to control. This symposium seeks to improve guideline adherence and help clinicians integrate antihypertensive therapies into the management of high-risk patient populations including the elderly (those 65 and older), African Americans, patients suff ering from heart failure, the obese, and individuals with diabetes and/or the metabolic syndrome. Case-based clinical scenarios and a panel discussion will clarify how best to integrate eff ective therapies into the management of patients with hypertension to reduce global cardiometabolic risk and improve clinical outcomes.

Supported by an educational grant from Forest Laboratories, Inc.

CME Breakfast Symposium B • 6:15 – 7:45am Innovations in GLP-1 Receptor Agonist Therapy:Individualized Treatment Strategies to Overcome Barriers and Reduce Cardiometabolic Risk in Type 2 Diabetes MellitusJohn B. Buse, MD, PhD (Chair); Samuel Dagogo-Jack, MD; Richard E. Pratley, MD

Some of the newer Type 2 diabetes therapies, including GLP-1 receptor agonists, do not carry the same limitations as traditional therapies. This class of drugs has been shown to improve global cardiometabolic risk factors and to improve the function of beta cells, rather than just address hyperglycemia. Our faculty will help clinicians understand the diff erences between GLP-1 receptor agonists, not only in terms of their mechanisms of action, but in terms of their impact on glucose control, beta cell function, and cardiovascular risk factors such as body weight, blood pressure, and lipid profi les. A review of current guideline recommendations will help clinicians appropriately integrate this class of medications into clinical practice to improve outcomes in the management of type 2 diabetes.

Supported by an educational grant from Lilly USA, LLC

CME Breakfast Symposium C • 6:15 – 7:45am New Targets and Treatments for LDL Lowering: Role of PCSK9 InhibitorsChristie M. Ballantyne, MD (Chair); Michael H. Davidson, MD;Marc S. Sabatine, MD, MPH; James A. Underberg, MD

Hypercholesterolemia is a major risk factor for cardiovascular diseases, increasing the incidence of myocardial infarction and death. However, patients on statin therapy who fail to reach their LDL-C treatment goal due to intolerance, poor therapeutic response, or severe familial hypercholesterolemia have few eff ective therapeutic options. Recent genetic insights have revealed novel therapeutic mechanisms that provide further LDL-C reductions on top of statin therapy. PCSK9 inhibitors are an emerging drug class designed to target and suppress the PCSK9 protein that prevents the body from removing LDL cholesterol from the bloodstream.

Supported by an educational grant from Amgen

See page 15

Only 2014 CMHC participants may register forCME Symposia & Professional Education.Seating is limited and available on a fi rst-come,

fi rst-serve basis. Register today!

CME SYMPOSIA

10 TITLE PAGE

PAGE TITLEPROGRAM OVERVIEW

PROGRAM OVERVIEW

Statement of Need*The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care professionals in the United States. The prevalence of most cardiometabolic risk factors – especially hyper tension, diabetes, and obesity – continues to rise. In the years ahead, American physicians should expect to treat unprecedented numbers of patients at high risk for morbidity and mor tality from cardiovascular disease. In 2000, approximately 32% of U.S. adults had the metabolic syndrome, a constellation of cardiometabolic risk factors including excessive abdominal fat, insulin resistance, dyslipidemia, and hyper tension.In more recent years that fi gure has climbed to 34%, and it may even be as high as 38%, depending on the criteria used to defi ne the syndrome.Patients with multiple cardiometabolic risk factors have twice the likelihood of developing and dying from cardiovascular disease and more than seven times the risk of developing diabetes, compared to those with no cardiometabolic risk factors. As the number of these patients increases, the burden of cardiovascular disease can be expected to increase in the United States as well. Unfor tunately , cardiovascular disease already aff ects approximately 82.6 million U.S. adults and is the leading cause of U.S. deaths. According to the American Hear t Association, cardiovascular disease causes more than 800,000 deaths each year – more than cancer and accidents combined. This is an average of more than 2,200 deaths per day , or one death ever y 39 seconds.ConclusionHealth care professionals play a major role in stemming the future burden of cardiovascular disease, diabetes, and associated comorbidities by employing aggressive strategies for the early identifi cation and comprehensive management of patients presenting with multiple cardiometabolic risk factors. The 2014 Cardiometabolic Health Congress will translate the latest cutting- edge medical research into practical, clinical approaches for preventing, delaying, and managing cardiovascular and metabolic risk . The goal is to provide the medical community with evidence -based inter ventions to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.* To access the 2014 CMHC full statement of need and reference list, please visit www .cardiometabolichealth.org/2014/accreditation.asp

Target Audience & Learning ObjectivesThe CMHC is designed for advanced-level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk. At the end of the congress, par ticipants will be able to:1. Explain the interrelationships among the various cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities.2. Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.3. Identify which inter ventions, including lifestyle changes and various drugs in combination, are most appropriate for par ticular patients based on their risk profi les.4. Identify how novel and emerging therapies can be integrated into clinical practice to reduce morbidity and mor tality from cardiovascular and metabolic disease.Purpose StatementTo improve patient outcomes through early identifi cation and inter vention strategies for patients with, or at risk of developing, diabetes and cardiovascular disease.

Only 2013 CMHC participants may registeSeating is limited and available on

10 CME SYMPOSIA

Friday, October 24, 2014 (continued)CME Lunch Symposium A • 12:30 – 2:00pmTriglyceride and Mixed Dyslipidemia Management:The Changing Landscape of CV Risk ReductionChristie M. Ballantyne, MD (Chair); Terry A. Jacobson, MD;Michael Miller, MD; Dariush Mozaff arian, MD, DrPH

Triglycerides are an increasingly important consideration when assessing cardiovascular risk. This symposium will address the prevalence of untreated hypertriglyceridemia and the importance of managing triglycerides to reduce cardiovascular risk. Recognized experts will discuss current guideline recommendations for hypertriglyceridemia and present data on new and emerging treatment options with a focus on comparing and contrasting the clinical data on prescription omega-3 fatty acids and novel combination therapies.

Supported by an educational grant from AstraZeneca

CME Lunch Symposium B • 12:30 – 2:00pmNew Frontiers in Obesity Management:Advances in Neurobiological Treatment StrategiesCaroline M. Apovian, MD (Chair); Louis J. Aronne, MD;Lee M. Kaplan, MD, PhD; Joshua Thaler, MD, PhD

New discoveries related to physiologic neuroendocrine mechanisms that mediate appetite regulation and energy balance as well as the relationship between obesity and related comorbidities have created a need for education. This symposium will review the recent advances in knowledge regarding the neurobiological basis of obesity, the complexities of central nervous system (CNS) involvement, and how new and emerging therapeutic options work with the CNS to regulate body weight. Attendees will receive guidance on how to select obesity therapies that are safe, eff ective, and individualized to support obese patients during various stages of weight loss.

Supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Orexigen

CME Lunch Symposium C • 12:30 – 2:00pmIndividualizing Therapy in Patients with Stable Ischemic Heart Disease: Managing the Full Spectrum of Comorbidities and CardiometabolicRisk FactorsJoAnne M. Foody, MD (Chair); Suzanne V. Arnold, MD;Deepak L. Bhatt, MD, MPH; Peter H. Stone, MD

Approximately 10 million individuals in the U.S. have angina, with 500,000 new cases being diagnosed each year. Cardiovascular risk reduction for patients with Stable Ischemic Heart Disease (SIHD) should focus on appropriate evaluation and diagnosis of symptoms to guide treatment and management of concomitant risk factors. This symposium will review the updated guidelines for the diagnostic and treatment of patients with SIHD, with a focus on select comorbidities, such as gender, heart failure, and diabetes. Faculty will also discuss appropriate risk-stratifi cation and decision-making strategies to determine which patients should receive revascularization and which patients should be managed with medication.

Supported by an educational grant from Gilead Sciences, Inc.

CME Dinner Symposium A • 7:00 – 9:00pmImproving Awareness and Outcomes in Lipodystrophy Syndromes: Clinical Manifestations, Diagnosis, and Evolving Therapeutic StrategiesAbhimanyu Garg, MD (Chair); Rebecca J. Brown, MD;Elif A. Oral, MD; Andra Stratton

This symposium, endorsed by Lipodystrophy United (LU), will discuss the signs and symptoms of lipodystrophy, a rare disorder characterized by selective loss of adipose tissue. If not adequately treated, patients with lipodystrophy remain at risk for severe life‐threatening complications and chronic morbidity, such as pancreatitis, end-stage liver or renal disease, accelerated atherosclerosis, and cardiomyopathy. The faculty will explain the metabolic consequences of the disease and present evidence-based treatment recommendations. A Lipodystrophy United Patient Advocate will provide the unique perspective of an individual living with the disease to help overcome common barriers to early recognition and treatment.

Supported by an educational grant from AstraZeneca | Endorsed by Lipodystrophy United

CME Dinner Symposium B • 7:00 – 9:00pmIntegrated Management of the Complexities of Cardiometabolic Diseases: A Patient-Centric Team ApproachLawrence Blonde, MD; Honey E. East, MD;Martha M. Funnell, MS, RN, CDE; Daniel M. Riche, PharmD

Implementation of the Patient Protection and Aff ordable Care Act has increased the emphasis on collaboration and teamwork in chronic disease management, the medical home and patient self-management. This unique symposium will discuss the challenges of managing the complex cardiometabolic patient and ways in which a multidisciplinary team approach with a focus on patient empowerment can reduce morbidity/mortality and improve long-term patient outcomes. Expert faculty will provide case examples demonstrating strategies for providing integrated care to type 2 diabetes patients with multiple risk factors.

Supported by an educational grant from Merck & Co., Inc.

Saturday, October 25, 2014CME Breakfast Symposium • 6:15 – 7:45amOvercoming Obstacles in Obesity Management:New Tools, Techniques, and Treatment StrategiesLouis J. Aronne, MD (Chair); Caroline M. Apovian, MD; Harold E. Bays, MD; Thomas A. Wadden, PhD

Lifestyle interventions focused on diet, physical activity and behavioral therapy are essential to treating obesity and should be incorporated throughout the continuum of care. While some individuals do manage to lose weight through diet and lifestyle changes, long-term weight loss and maintenance is diffi cult to achieve for many. New and emerging pharmacologic therapies have the potential to signifi cantly impact the management of obesity and reduce the associated cardiometabolic risk. During this symposium, expert faculty will review the mechanisms of action and clinical and safety profi les of prescription weight loss agents, describe eff ective patient counseling techniques for achieving and maintaining weight loss, and provide techniques to develop a weight and complications-centric approach to obesity management.

Supported by an educational grant from Eisai, Inc.

Agenda and faculty are subject to change.

Check cardiometabolichealth.org for updates and fi nal symposia options.

Statement of NeedThe ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care providers in the United States. Current estimates suggest approximately 23% to 38% of all U.S. adults have metabolic syndrome, a constellation of cardiometabolic risk factors, including excessive abdominal fat, insulin resistance, infl ammation, dyslipidemia, and hypertension. Patients with multiple cardiometabolic risk factors have twice the likelihood of developing and dying from cardiovascular disease and more than seven times the risk of developing diabetes compared with those with no cardiometabolic risk factors. Cardiovascular disease already aff ects approximately 83.6 million U.S. adults (greateer than 1 in 3) and is the leading cause of U.S. deaths; however, this CVD burden can be expected to increase.

This sampling of sobering statistics points to a rapidly growing epidemic of cardiovascular and metabolic disease and calls to the forefront the need for medical education focused on all aspects of cardiometabolic risk. The CMHC presents an especially valuable venue for this educational outreach with sessions fostering a collaborative, multidisciplinary approach to care.

The 2014 Cardiometabolic Health Congress will translate the latest cutting-edge medical research into practical, clinical approaches for preventing, delaying, and managing cardiovascular and metabolic risk. The goal is to provide the medical community with evidence-based interventions to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.

Target Audience & Learning ObjectivesThe CMHC is designed for advanced-level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk.

At the end of the Congress, participants will be able to:

1. Explain the interrelationships among the various cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities.

2. Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.

3. Identify which interventions, including lifestyle changes and various drugs in combination, are most appropriate for particular patients based on their risk profi les.

4. Identify how novel and emerging therapies can be integrated into clinical practice to reduce morbidity and mortality from cardiovascular and metabolic disease.

Purpose StatementTo improve patient outcomes through early identifi cation and intervention strategies for patients with, or at risk of developing, diabetes and cardiovascular disease.

Disclosure of Confl icts of InterestIt is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientifi c rigor in all of its educational activities. In accordance with this policy, MER identifi es confl icts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Confl icts are resolved by MER to ensure that all scientifi c research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Physician CreditThis activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources and HealthScience Media, Inc.Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.

Credit DesignationMedical Education Resources designates this live activity for a maximum of 27.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP (American Academy of Family Physicians) CreditThis Live activity, Cardiometabolic Health Congress, with a beginningdate of 10/22/2014, has been reviewed and is acceptable for up to 27.50Prescribed credit(s) by the American Academy of Family Physicians.Physicians should claim only the credit commensurate with the extentof their participation in the activity.

Nursing Credit (ANCC)Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 27.5 contact hours of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 27.5 contact hours.

AANP (American Academy of Nurse Practitioners) CreditThis program is approved for 27.5 contact hour(s) of continuingeducation (which includes 22.0 hours of pharmacology) by theAmerican Association of Nurse Practitioners. Program ID 1408362. Thisprogram was planned in accordance with AANP CE Standardsand Policies and AANP Commercial Support Standards.

Registered Dietitian CreditMedical Education Resources is an accredited CPE provider for the Commission on Dietetic Registration.

Pharmacy CreditMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 27.5 contact hours (2.75

CEUs) of the Accreditation Council for Pharmacy Education. (Universal Program Number – 0816-9999-14-002-L01-P)

Physician Assistants: AAPA accepts certifi cates of participation for educational activities certifi ed for Category I credit from AOACCME, Prescribed credit from AAFP and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. The 2014 Cardiometabolic Health Congress (CMHC) is accredited by Medical Education Resources (MER). MER is accredited by the ACCME, ANCC, ACPE, and the CDR to provide continuing medical education. Physician Assistants may receive a maximum of 27.5 hours of Category I credit for completing this program.

Certifi ed Diabetes Educators: The 2014 Cardiometabolic Health Congress (CMHC) is accredited by Medical Education Resources (MER). MER is accredited by the ACCME, ANCC, ACPE, and the CDR to provide continuing medical education. All of these accredited organizations are recognized by the AADE when applying for CDE renewal of certifi cation or for initial certifi cation.

PROGRAM OVERVIEW & ACCREDITATION

PROGRAM OVERVIEW & ACCREDITATION 11

WEDNESDAY • OCTOBER 22, 2014

FACULTY

PROFESSIONAL EDUCATION (non-CME)

7:00 – 8:30pm • Dinner

New Diagnostic Tools for the Prevention and

Comprehensive Management of Diabetes

Timothy E. Graham, MDSponsored by Health Diagnostic Laboratory, Inc. Timothy E. Graham, MD

Assistant Professor of Medicine,Endocrinology, Diabetes, and Metabolism,Biological Chemistry, and Nutrition

11:15am – 12:30pm

The Eff ect of a Once-Weekly Therapy on A1C

and Weight Over 3 Years

Neil I. Kaminsky, MDSponsored by AstraZeneca Diabetes

12:30 – 2:00pm • Lunch

Advancing Paradigm Changes in

Type 2 Diabetes Management

Robert Busch, MDSponsored by Janssen Pharmaceuticals, Inc.

Robert Busch, MDEndocrinologistThe Endocrine Group

Neil I. Kaminsky, MDEndocrinologist Presbyterian Medical GroupAlbuquerque, NM

2:00 – 3:15pm

Addressing Chronic Weight Management

with Targeted Pharmacotherapy

Harold E. Bays, MDSponsored by Eisai, Inc.

Harold E. Bays, MDMedical Director/PresidentLouisville Metabolic and AtherosclerosisResearch Center, Inc.

4:30 – 5:45pm

SGLT2 Inhibition: A Glucuretic Treatment Option for

Your Adult Patients With Type 2 Diabetes

Neil I. Kaminsky, MDSponsored by AstraZeneca Diabetes

5:45 – 7:00pm

Chronic Weight Management in Adults: A Treatment OptionHarold E. Bays, MDSponsored by Takeda Pharmaceuticals America, Inc.

FRIDAY • OCTOBER 24, 20146:00 – 7:00pm

Take a Closer Look at Homozygous

Familial HypercholesterolemiaDaniel E. Wise, MD

Sponsored by Aegerion Pharmaceuticals

6:00 – 7:00pm

Treatment Considerations for Generalized LipodystrophyJean Chan, MD

Sponsored by AstraZeneca

3:15 – 4:30pm

Understanding High Triglycerides

JoAnne M. Foody, MDSponsored by AstraZeneca

JoAnne M. Foody, MDAssociate ProfessorHarvard Medical SchoolMedical DirectorCardiovascular Wellness ProgramBrigham and Women’s Hospital

Jean Chan, MDEndocrinologistSan Diego, CA

Daniel Wise, MDCardiology Specialists of the Carolinas PA

Round out your CMHC educational experience by attending Professional Education symposia focused on novel therapies

and diagnostic testing. These non-certifi ed activities are not part of the offi cial CMHC program and are planned solely by

the sponsoring organizations/companies. There are no fees to attend and meals or refreshments may be provided.

12 PROFESSIONAL EDUCATION

Arrive Early for a Chance towin an iPad Mini or an iMac!

Check-in at the CMHC Registration desk by11:00am on Wednesday, October 22 to be entered into this exclusive raffl e.

EXHIBITOR INFORMATION 13

Aegerion Pharmaceuticals Amarin Pharma Inc. American College of Cardiology Amgen Inc. Arbor Pharmaceuticals AstraZeneca AstraZeneca Diabetes Atherotech Diagnostics Lab Boston Heart Diagnostics Cardiometabolic Health Congress Cardio Renal Society of America Cell Science Systems diaDexus, Inc. Eisai, Inc. Enovative Technologies Genova Diagnostic Genzyme, A SANOFI COMPANY

Gilead Sciences, Inc. Health Diagnostic Laboratory, Inc. Healthy Habits Medical Consultants Ideal Protein of America Janssen Pharmaceuticals, Inc. Lilly LipoScience Meet the Experts Lounge Merck & Co., Inc. Metabolic Medical Institute, Inc. Nature-Throid Novo Nordisk, Inc. Otsuka America Pharmaceutical, Inc. Postgraduate Medicine Salix Pharmaceuticals, Inc. Takeda Pharmaceuticals U.S.A., Inc. The FH Foundation

2014 EXHIBITORS(as of October 8, 2014)

Meaningful relationships with your current and future customers to help grow your brand

through face-to-face discussions

BUILD

Multidisciplinary clinical experts seekingcutting-edge products and services to help

manage patients suff ering from cardiovascular and metabolic diseases

ENGAGE

High-level US-based practicing clinicians – the decision makers on the front lines of patient care

and cardiometabolic risk management

ACCESS

With our world-renowned faculty and collaborate with your key customers in a unique setting

INTERACT

WHY THE CMHCis the Premier

Sponsorship Opportunity…

Customized Sponsorship Packages AvailableThe most exposure for less with an integrated marketing package designed to suit your needs

2014 SPONSORSThe CMHC gratefully acknowledges the sponsorship provided

by the following organizations:

For information on becoming a 2014 CMHC sponsorplease call 877.571.4700 or email info@cardiometabolichealth.org

AstraZeneca Diabetes

Platinum Sponsor

Bronze SponsorsAmgenMerck

Novo Nordisk, Inc.Takeda Pharmaceuticals U.S.A., Inc.

Silver Sponsors

AstraZenecaEisai

Health Diagnostic Laboratory, Inc.

14 HOTEL & TRAVEL / SUPPORTERS

Faneuil Hall

Boston is a center for medical and scientific discoveries that offers historical ambience, beautiful parks,and great shopping and dining. This city truly has something for everyone:

• Follow the Freedom Trail on foot to learn about the historical people and events surroundingthe Revolutionary War, including Paul Revere and his famous ride to Lexington.

• Spend the day strolling through Boston Common, the oldest U.S. city park, or shopping on Boston’strendy Newbury Street.

• See the historic architecture in Faneuil Hall and grab lunch and souvenirs in Quincy Market.

Visit Boston’s official Convention and Visitors Bureau website for more sightseeing information: www.bostonusa.com

autiful parks,

unding

Boston’sg on B

rket.ar

tion: www.bostonussa.a.cocococommmmmm

Sheraton Boston Hotel 39 Dalton StreetBoston, MA 02199617.236.2000

To book your hotel room by phone, please contact the hotel directly. Mention that you have registered to attend the Cardiometabolic Health Congress to receive our special negotiated room rate.

The 2014 CMHC discounted room rate is available only until October 15, 2014, on a first-come, first-served basis. Rooms are limited and subject to availability.

To reserve your hotel accommodations online, visitwww.cardiometabolichealth.org/travel.asp

Publication SupportersAssociation Supporters American Heart AssociationCouncils on High Blood Pressure Research;

Stroke; Epidemiology & Preven on;CV Disease in the Young; Basic CV Sciences; Clinical Cardiology; CV and Stroke Nursing;

Lifestyle and Cardiometabolic Health

Metropolitan New York Associationof Diabetes Educators

San Francisco Bay AreaAssocia on of Diabetes Educators

New Jersey Coordina ngBody of AADE

Association of Physicians Assistants

in Cardiology

HOTEL & TRAVEL

REGISTRATION FORM 15

Total Amount Due

Method of Payment Check Visa MasterCard American Express Discover

Account Number Expiration Date

Cardholder Name Cardholder Signature

Cancellation PolicyCancellations must be made in writing via fax to 866.218.9168 or email to info@cardiometabolichealth.org. Refunds, less a $100 service fee, will be given if written cancellation is received no later than August 22, 2014. No refunds will be given after August 22, 2014. To send a substitute, please call 877.571.4700 or emailyour request to info@cardiometabolichealth.org.

Cardiology Endocrinology Internal Medicine Nephrology Primary Care Industry Other

* Must be engaged in clinical practice to receive discounted rate.** ID card from school, residency, or fellowship program is required for verifi cation. No other discounts apply.

Offi ce-based Hospital Academic Government Pharmacy Industry

Which best describes your primary workplace setting? (check one)

Register by 10/3/2014

Prefi x First Name Last Name Degree(s)

Title

Affi liation

Address 1

Address 2

City State Zip Code

Tel Fax

Email NPI # (required)

Please indicate your specialty: (check one)

2014

Current members of our Association Supporters receive a $100 discount off the registration price.Indicate which organization you are a member of below:

Online: www.cardiometabolichealth.org

Scan:Scan this code tocall us directly

Phone: 877.571.4700732.758.0030 – outside the USA

Fax:866.218.9168

Mail Registration Form with Payment:Cardiometabolic Health Congressc/o HealthScience Media, Inc.788 Shrewsbury Avenue, Suite 102Tinton Falls, NJ 07724

Alliance of Cardiovascular Professionals (ACVP)

American Academy of Pediatrics (AAP)

American Association of Heart Failure Nurses (AAHFN)

American Board of Obesity Medicine (ABOM)

American College of Cardiology (ACCF)

American College of Nutrition (ACN)

American College of Preventive Medicine (ACPM)

American Heart Association (AHA)

American Medical Women’s Association (AMWA)

American Society of Bariatric Physicians (ASBP)

American Society of Endocrine Physician Assistants (ASEPA)

American Society of Hypertension (ASH)

Asian Pacifi c Society of Cardiology (APSC)

Association of Black Cardiologists (ABC)

Association of Occupational Health Professionals in Healthcare (AOHP)

Association of Physician Assistants in Cardiology (APAC)

Cardio Renal Society of America (CRSA)

Consortium for Southeastern Hypertension Control (COSEHC)

Connecticut Alliance of Diabetes Educators (CADE)

Coordinating Body of AADE of Massachusetts (DEEM)

European Society of Lifestyle Medicine (ESLM)

Foundation of European Nurses in Diabetes (FEND)

Granite State Diabetes Educators (GSDE)

International Association for the Study of Obesity (IASO)

International Atherosclerosis Society (IAS)

International Society on Hypertension in Blacks (ISHIB)

Latino Diabetes Association (LDA)

Metropolitan New York Association of Diabetes Educators (MNYADE)

National Association of Bariatric Nurses (NABN)

National Association of Chronic Disease Directors (NACDD)

National Board of Physician Nutrition Specialists (NBPNS)

National Kidney Foundation (NKF)

NJ Coordinating Body of AADE (NJCB)

Northern Indiana Association of Diabetes Educators (NIADE)

Obesity Action Coalition (OAC)

San Francisco Bay Area Assoc. of Diabetes Educators (SFBAADE)

Society for the Study of Ingestive Behavior (SSIB)

Society of Cardiovascular Computed Tomography (SCCT)

Society of Invasive Cardiovascular Professionals (SICP)

STOP Obesity Alliance (STOP)

The Obesity Society (TOS)

World Heart Federation (WHF)

LAST CHANCE TO SAVE UP TO $300

Physicians*

Allied Health Professionals*

Residents/Fellows**

Industry

Registration FeesRegister By

10/16/2014

$795

$695

$300

$1,295

Register Onsite

beginning 10/22/2014

$895

$795

$350

$1,395

Register By

10/21/2014

$850

$750

$325

$1,350

Special Online Only Pricing